MEDRAD to Recognize 39 Employee Inventors and Authors
 at Awards Dinner

FOR IMMEDIATE RELEASE

For additional information contact:

Luanne M. Radermacher, Corporate Communications
412-767-2400 ext. 3184

Dan Dieter, Product Communications
412-767-2400 ext. 3726

INDIANOLA, Pa., May 23, 2006 – On May 25, 2006, MEDRAD will honor 39 employee inventors and authors who have collectively generated 22 medical device patents and technical publications, enabling the company to deliver on its mission to improve the quality of healthcare. The patents and publications represent MEDRAD’s commitment to research and development and were submitted by teams of scientists, engineers and marketers charged with forging the next generation of MEDRAD products.

“MEDRAD’s growth is and has always been fueled by innovation and technological advancements. These thirty-nine inventors, through their collective creativity and ingenuity, have helped to improve the quality of healthcare and enable MEDRAD’s continued growth. We owe a great deal to their talent, effort and contribution,” remarked Joe Havrilla, chief technology officer.

MEDRAD has a long history of innovation, beginning with founder M. Stephen Heilman, M.D.’s invention of the first angiographic injector in 1966. An emergency room physician by day, “Doc” created a machine to power inject contrast agent into the vessels during an angiogram procedure, making it possible to better diagnose his heart disease and stroke patients. MEDRAD went on to develop the first injection systems for CT, MR and ultrasound and the first MR-compatible infusion system.

The annual recognition dinner will take place at J. Verno’s Studio on Pittsburgh’s South Side with John P. Friel, President and CEO of MEDRAD, INC., as the keynote speaker. Other speakers include Joe Havrilla and Greg Bradley, executive director of corporate intellectual property.

Awards will be presented to these patent holders and authors:

MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD’s product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2005 revenues were $411 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company’s world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a U.S. affiliate of Schering AG, Germany (FSE:SCH; NYSE:SHR).

Cautionary Statement Regarding Forward-Looking Statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Medrad’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Medrad undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events, circumstances or otherwise.